|
**Overview**: JC Virus Quantitative PCR Panel**Introduction**: The JC Virus Quantitative PCR Panel is a diagnostic tool designed to quantify JC virus load using plasma or CSF samples. In India, JC virus (JCV) causes progressive multifocal leukoencephalopathy (PML) in immunocompromised patients (HIV, transplant, MS on natalizumab), with high mortality (~50 percent) if untreated. High morbidity from under-testing in rural/low-SES HIV or transplant patients with neurological symptoms, limited PCR labs, delayed discontinuation of immunosuppressants or mirtazapine leading to rapid progression. Per microbiology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for JC virus RNA, viral load, and quantitative result over 1-2 days with high sensitivity, valuable for PML diagnosis and monitoring. This diagnostic falls under viral load monitoring and targets immunocompromised patients with CNS symptoms, addressing accurate detection to guide immune reconstitution or supportive care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise JCV assessment and reducing PML mortality. Its plasma/CSF-based approach ensures reliable viral quantification.**Other Names**: JC Virus PCR Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/molecular pathology, compliant with 2025 standards.**Historical Milestone**: JCV PCR standard for PML; in India, used in neuro-HIV clinics.**Purpose**: The test assesses 3 parameters including JC Virus RNA to guide viral load monitoring, confirm PML, inform management.**Test Parameters**: 1. JC Virus RNA, 2. Viral Load, 3. Quantitative Result.**Pretest Condition**: No fasting required; patients should have immunosuppression and neurological symptoms.**Specimen**: 3 mL plasma (EDTA) or CSF (sterile container), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve RNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on immunosuppression, CNS symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed PML including mortality, benefits of quantification, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low viral load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Detectable JCV in CSF with symptoms indicates PML, necessitating specialist input.**Specialist Consultation**: Neurologists or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: MRI brain, CSF cytology for confirmation.**Test Limitations**: CSF preferred for PML; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Neurovirology Studies India 2023. |
